Skip to main content
. 2019 Nov 30;8(1):34–40. doi: 10.1016/j.prnil.2019.10.004

Table 2.

Risk stratification

Risk Group Control (n = 58) Celecoxib (n = 60) Meloxicam (n = 53) P value
Risk group
 Low 13.8% (n = 8) 3.3% (n = 2) 6.2% (n = 3) 0.189
 Intermediate 31.0% (n = 18) 40.0% (n = 24) 39.6% (n = 19)
 High 55.2% (n = 32) 56.7% (n = 34) 54.2% (n = 26)

Low risk = Diagnostic PSA <10 ng/mL, Gleason score ≤6 and stage T1c or T2a, Intermediate = Diagnostic PSA of 10-20 ng/mL or Gleason score of 7 or cancer stage T2b, High = Diagnostic PSA > 20 ng/mL or Gleason score of 8-10 or cancer stage of T2c/T3.